Percutaneous treatment of orofacial vascular malformations

SİNDEL A., SAYAN A., ÖZGÜR Ö., Sindel T., ILANKOVAN V.

BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, cilt.56, sa.3, ss.206-211, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.bjoms.2018.01.013
  • Dergi Adı: BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.206-211
  • Anahtar Kelimeler: bleomycin, sclerosing agent, vascular malformation, percutaneous treatment, fluoroscopy, VENOUS MALFORMATIONS, HEMANGIOMAS, SCLEROTHERAPY, CLASSIFICATION, EMBOLIZATION, DIAGNOSIS, BLEOMYCIN, ANOMALIES, CHILDREN, THERAPY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

The aim of this study was to evaluate the efficacy of fluoroscopy-guided percutaneous injection of bleomycin as the primary treatment for low-flow vascular malformations. A total of 34 patients (mean (range) age 24 (8-51) years) with orofacial vascular lesions were treated in the Department of Interventional Radiology and Maxillofacial Surgery. There were 20 low-flow venous malformations, 11 lymphatic malformations, and three of mixed type. All patients were treated by fluoroscopy-guided percutaneous injection of a mixture of bleomycin (mean (range) 15 (5-15) mg) and a radio-opaque agent (Ultravist (R) (iopromide), Bayer)/session. The number of sessions ranged from one to six. The clinical response was complete in 21 patients, obvious in nine, and of clinical benefit in four. Patients were reviewed within the first week, third week, and at three-month periods until 24 months. There were no serious complications such as pulmonary fibrosis. Fluoroscopy-guided intralesional injection of bleomycin should be considered as the first-line treatment for lymphatic malformations because it is effective and reliable with few complications. Crown Copyright (c) 2018 Published by Elsevier Ltd on behalf of The British Association of Oral and Maxillofacial Surgeons. All rights reserved.